Research progress on the effect of hepatitis B virus DNA integration on antiviral therapy

VernacularTitle:乙型肝炎病毒?DNA?整合及抗病毒治疗对其作用的研究进展
Author: Jing ZHAO ¹ ; Xinyue CHEN ; Sujun ZHENG
Author Information

1. 首都医科大学附属北京佑安医院肝病中心一科，北京　100069
Keywords: Hepatitis B virus; DNA integration; Clinical cure; Hepatocellular carcinoma; Nucleos(t)ide-analogues; Interferon
From: Chinese Journal of Hepatology 2024;32(4):375-379
CountryChina
Language:Chinese
Abstract: Hepatitis B virus (HBV) DNA integration occurs during the reverse transcription process of HBV replication, which develops in the early stages of HBV infection and accompanies the entire disease course. The integration of HBV DNA is detrimental to the attainment of clinical cure goals and also raises the risk of developing liver cancer. Theoretically, nucleos(t)ide analogs can reduce the synthesis of new double-stranded linear DNA, but there is no clearance function for hepatocytes that have already integrated HBV. Therefore, patients with serum HBV DNA-negative conversions still have the risk of developing liver cancer. As an immunomodulatory drug, interferon can not only inhibit viral replication but also inhibit or even eliminate existing clonally amplified hepatocytes carrying integrated HBV DNA fragments. However, there are currently few studies on the effects of nucleos(t)ide analogues and interferon therapy on HBV DNA integration. Thus, large-scale clinical studies are urgently needed for further clarification.